September is #WorldAlzMonth, a time to raise awareness and take action against the growing impact of #Alzheimers disease. As the prevalence of this condition continues to rise, our commitment to advancing research remains steadfast, with a focus on slowing disease progression and driving innovation in preventive therapies.
Über uns
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.
- Website
-
http://www.prothena.com
External link for Prothena Corporation
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Dublin, 2
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2012
Standorte
-
Primäre
77 Sir John Rogerson's Quay, Block C
Grand Canal Docklands
Dublin, 2 D02 T804, IE
-
331 Oyster Pt. Boulevard
South San Francisco, CA 94080, US
Employees at Prothena Corporation
Aktualisierungen
-
The ASCENT clinical trials are now enrolling patients 55 to 85 years of age with a confirmed or suspected diagnosis of mild Alzheimer's disease or mild cognitive impairment due to Alzheimer’s disease. Learn more about how you or a loved one can participate: https://www.ascent-ad.com
-
Tomorrow marks the start of #ESC2024 in London! We look forward to engaging in meaningful discussions and collaborations with the #cardiology and #amyloidosis community. Learn more about the event: https://bit.ly/4dCUdu3
-
At Prothena, we understand that workplace culture extends beyond productivity—it reflects our core values. Director of Regulatory Operations, Michael Finkle, shares how our commitment to fostering a positive and inclusive culture is rooted in our mission to prioritize the patient communities we serve. #ProthenaProud
-
#WomensEqualityDay inspires us to reflect on how we can further empower women in our industry. Today, Vice President, Product Team Lead, Mary (Mimi) DeSouza offers her insights on the importance of integrating inclusion in the workplace and its meaningful impact.
-
Equipping patients with the knowledge they need to understand and manage their condition is essential for diseases with non-specific symptoms such as #amyloidosis. Explore resources from the Amyloidosis Research Consortium (ARC) for insights on GI tract impacts and management techniques: bit.ly/3yRvOl9
-
AL #amyloidosis can present in many different ways, making it challenging to diagnose, especially in its early stages. Hear firsthand perspectives from those living with this #raredisease and the challenges faced in putting the puzzle pieces together: https://bit.ly/471coHi
-
This year, our team had the honor to participate in the Amyloidosis Foundation Virtual Run/Walk/Roll/Bike Event, spreading awareness in support of #amyloidosis within our local communities. Despite our team being spread across the US and EU, distance did not deter us in coming together for this meaningful event! #RunForAmyloidosis
-
Amyloid light chain (AL) #amyloidosis is a progressive plasma cell disorder in which amyloid builds up in tissues and organs, disrupting their normal function. Understanding its pathophysiology—how it develops and affects the body—is essential for advancing treatment and improving patient outcomes. Hear from our Chief Medical Officer, Hideki Garren, as he recently sat down with CheckRare to discuss the mechanisms of this #raredisease, shedding light on the latest research: https://bit.ly/3AqScSN
-
Participating in #clinicaltrials plays a key role in driving the development of treatment options for patients. We're currently enrolling participants for several studies for neurodegenerative and rare peripheral amyloid diseases, including #AlzheimersDisease and AL #amyloidosis. For additional information, visit: bit.ly/3YBZygv
Ähnliche Seiten
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 172.4M